Publication
Title
A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix (TM)) is immunogenic and well tolerated in adults
Author
Abstract
Reduced-antigen-content diphtheria-tetanus-acellular-pertussis (dTpa) vaccines are predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix (TM), GlaxoSmithKline Biologicals) administration in 164 adults previously vaccinated with dTpa 10 years previously was evaluated. Before the decennial booster, 89.4% and 94.8% subjects were seroprotected (antibodies >= 0.1 IU/mL) for diphtheria and tetanus, respectively. One-month post-booster, all subjects were seroprotected/seropositive against all vaccine antigens. Robust GMC increases indicated a booster response similar to the first booster. The decennial booster was well tolerated without serious adverse events, consistent with product experience. This study supports replacing traditional Td boosters with dTpa, and use of Boostrix (TM) as a decennial booster. This study is registered at www.clinicaltrials.com NCT00548171. (C) 2010 Published by Elsevier Ltd.
Language
English
Source (journal)
Vaccine / International Society for Vaccines. - Amsterdam
Publication
Amsterdam : 2010
ISSN
0264-410X
DOI
10.1016/J.VACCINE.2010.10.025
Volume/pages
29 :1 (2010) , p. 45-50
ISI
000286345000007
Pubmed ID
20974302
Full text (Publisher's DOI)
UAntwerpen
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 19.10.2020
Last edited 15.11.2022
To cite this reference